Pre-Due Diligence Assessment of First-in-Class Allergy Therapeutic

Challenge: A pharmaceutical company seeking new assets requested a pre-due diligence assessment of a European biotech developing a first-in-class compound for treating allergic conditions. The...
Learn More

Strategic Partnership Assessment of Autoimmune Drug Development Program

Challenge: A pharmaceutical client asked Alacrita to assess a early-stage biotech company developing an orally-available agent for treating various autoimmune conditions. The pharma company was...
Learn More

Pre-Due Diligence Assessment of a Women's Health Biotech Partnership

Challenge: A pharmaceutical company was actively searching for strategic partnering opportunities to expand its pipeline and had commissioned Alacrita to conduct a comprehensive pre-due diligence...
Learn More

Due Diligence of an Academic Adenovirus Gene-Therapy Program

Challenge: A pharmaceutical company with an established gene-therapy franchise wanted to expand its oncology pipeline through external licensing. Among several options, the deal team had identified...
Learn More

Revamped corporate pitch deck and partnering deal terms for European biotech

Project Challenge: A European biotech company was developing next-generation ADC payloads with at least as good intracellular cytotoxicity properties as other payloads used in ADCs, but with a much...
Learn More

Benchmarking deal terms & formulating negotiating positions for AI discovery company

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...
Learn More

Assessing a new inhalation device and assisting with partnering

Challenge: A medical device company has developed a nebulizer system for pulmonary delivery that can produce droplets below 1.5µm diameter. Initial clinical evaluations of demonstrator compounds used...
Learn More

Provision of support for creating an investor prospectus

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...
Learn More

Out-licensing support for a dengue vaccine

Challenge A company was developing a unique dengue vaccine which it planned to out-license to a Big Pharma partner. Alacrita was commissioned to provide business development support to identify a...
Learn More

Rare disease landscape and acquisition screening

Challenge Our client, a mid-cap research-based pharmaceutical company, had enjoyed striking success with a rare disease product which had different market dynamics to the bulk of the company's...
Learn More

Presenting technology & clinical programs at ASH & SABCS

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its technology and...
Learn More

Deal analysis for an anti-anaemia product

Challenge: An investor group was facing its first potential deal in the pharmaceuticals sector. It had pre-negotiated a deal with a group that had invented an approach to treating...
Learn More
1 2
Next

Alacrita Consulting, Limited
UK, Europe & Asia
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608

Alacrita Consulting, Inc.
US
One Broadway
Floor 14
Cambridge, MA 02142

Registered in Delaware

© 2009 - 2025 Alacrita Holdings Limited

Privacy Policy | Pharmaceutical Consulting